Current Environment: Production

Medical Services

Programs & Services

Languages

  • English
  • Russian

Education

Medical School

Harvard Medical School

2007, Boston, MA

Internship

Boston Combined Residency Program (BCRP)

2008, Boston, MA

Residency

Pediatrics

Boston Combined Residency Program (BCRP)

2010, Boston, MA

Fellowship

Pediatric Hematology/Oncology

Boston Children's Hospital/Dana-Farber Cancer Institute

2013, Boston, MA

Certifications

  • American Board of Pediatrics (Hematology-Oncology)

Publications

  1. CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias. bioRxiv. 2024 Dec 30. View Abstract

  2. Nucleotide depletion promotes cell fate transitions by inducing DNA replication stress. Dev Cell. 2024 08 19; 59(16):2203-2221.e15. View Abstract

  3. Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML. Blood. 2024 04 11; 143(15):1513-1527. View Abstract

  4. Pathophysiology of Acute Myeloid Leukemia. Acta Haematol. 2024; 147(2):229-246. View Abstract

  5. Inherent genome instability underlies trisomy 21-associated myeloid malignancies. Leukemia. 2024 03; 38(3):521-529. View Abstract

  6. Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML. Sci Transl Med. 2024 01 03; 16(728):eade2774. View Abstract

  7. IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia. Biomedicines. 2024 Jan 01; 12(1). View Abstract

  8. ETV6 fusions from insertions of exons 3-5 in pediatric hematologic malignancies. Haematologica. 2023 12 01; 108(12):3471-3476. View Abstract

  9. Treatment of recurrent pediatric myelodysplastic syndrome post hematopoietic stem cell transplantation. Clin Case Rep. 2023 Nov; 11(11):e8190. View Abstract

  10. Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma. Clin Cancer Res. 2023 11 14; 29(22):4613-4626. View Abstract

  11. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv. 2023 11 14; 7(21):6685-6701. View Abstract

  12. Outlier Expression of Isoforms by Targeted or Total RNA Sequencing Identifies Clinically Significant Genomic Variants in Hematolymphoid Tumors. J Mol Diagn. 2023 09; 25(9):665-681. View Abstract

  13. Impact of cytoreduction and remission status on hematopoietic cell transplantation outcomes in pediatric myelodysplastic syndrome and related disorders. Pediatr Blood Cancer. 2023 Jun 27; e30530. View Abstract

  14. A single-institution pediatric and young adult interventional oncology collaborative: Novel therapeutic options for relapsed/refractory solid tumors. Cancer Med. 2023 06; 12(12):13300-13308. View Abstract

  15. Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts. Cancer Discov. 2022 07 06; 12(7):1760-1781. View Abstract

  16. Rapid next-generation sequencing aids in diagnosis of transient abnormal myelopoiesis in a phenotypically normal newborn. Blood Adv. 2022 05 10; 6(9):2893-2896. View Abstract

  17. IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. Nat Cancer. 2022 05; 3(5):595-613. View Abstract

  18. Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells. Cell Rep. 2022 04 26; 39(4):110752. View Abstract

  19. The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. 2022 02 10; 139(6):894-906. View Abstract

  20. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood. 2022 01 27; 139(4):538-553. View Abstract

  21. Targeting serine hydroxymethyltransferases 1 and 2 for T-cell acute lymphoblastic leukemia therapy. Leukemia. 2022 02; 36(2):348-360. View Abstract

  22. Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Sci Transl Med. 2021 03 31; 13(587). View Abstract

  23. Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discov. 2021 06; 11(6):1424-1439. View Abstract

  24. Corrigendum. Pediatr Blood Cancer. 2021 Mar; 68(3):e28885. View Abstract

  25. Targeting the Ras pathway in pediatric hematologic malignancies. Curr Opin Pediatr. 2021 02 01; 33(1):49-58. View Abstract

  26. Targeting the Ras pathway in pediatric hematologic malignancies. Curr Opin Pediatr. 2020 Dec 29; Publish Ahead of Print. View Abstract

  27. Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 01; 68(1):e28719. View Abstract

  28. The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. Cancer Discov. 2020 12; 10(12):1894-1911. View Abstract

  29. Targeting EZH2 for the treatment of hepatosplenic T-cell lymphoma. Blood Adv. 2020 04 14; 4(7):1265-1269. View Abstract

  30. Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia. Cancer Discov. 2020 02; 10(2):214-231. View Abstract

  31. Targeted therapy for fusion-driven high-risk acute leukemia. Blood. 2018 09 20; 132(12):1241-1247. View Abstract

  32. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 07; 65(7):e27062. View Abstract

  33. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 03 07; 10(431). View Abstract

  34. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med. 2017 Mar; 23(3):301-313. View Abstract

  35. Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2017 Feb 15; 23(4):1012-1024. View Abstract

  36. Targeting MTHFD2 in acute myeloid leukemia. J Exp Med. 2016 06 27; 213(7):1285-306. View Abstract

  37. A Prospective Cohort Quality Improvement Study to Reduce the Time to Antibiotics for New Fever in Neutropenic Pediatric Oncology Inpatients. Pediatr Blood Cancer. 2016 Jan; 63(1):112-7. View Abstract

  38. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014 Feb 10; 25(2):226-42. View Abstract

  39. Pulmonary hypertension associated with scurvy and vitamin deficiencies in an autistic child. Pediatrics. 2013 Dec; 132(6):e1699-703. View Abstract

  40. The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest. 2009 Apr; 119(4):852-64. View Abstract

  41. Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Exp Hematol. 2008 Nov; 36(11):1471-9. View Abstract

  42. The CDK-activating kinase (CAK) Csk1 is required for normal levels of homologous recombination and resistance to DNA damage in fission yeast. PLoS One. 2008 Jan 30; 3(1):e1492. View Abstract

  43. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders. Curr Opin Oncol. 2007 Nov; 19(6):628-34. View Abstract

  44. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006 Nov 15; 108(10):3472-6. View Abstract

  45. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006 Jul; 3(7):e270. View Abstract

  46. Peters anomaly in association with multiple midline anomalies and a familial chromosome 4 inversion. Ophthalmic Genet. 2006 Jun; 27(2):63-5. View Abstract

  47. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc Natl Acad Sci U S A. 2005 Dec 27; 102(52):18962-7. View Abstract
BESbswy